Drug Profile
Research programme:anti-infective therapeutics - AiCuris/Ligand Pharmaceuticals
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator AiCuris; Ligand Pharmaceuticals
- Class Anti-infectives; Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Gram-negative-infections in Germany
- 28 Oct 2020 No recent reports of development identified for research development in Gram-negative-infections in USA
- 06 Sep 2016 Early research in Gram-negative infections in Germany, USA, before September 2016 (AiCuris pipeline, September 2016)